jakavi
novartis europharm limited - ruxolitinib (kao fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastična sredstva - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Полицитемия vjera (mf)jakavi indiciran za liječenje odraslih bolesnika s полицитемия vjera, koje su otporne na ili netoleranciju hidroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
opzelura
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostali dermatološki pripravci - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
jakavi 5 mg/1 tableta tableta
novartis ba d.o.o. - ruksolitinib - tableta - 5 mg/1 tableta - 1 tableta sadrži: 5 mg ruksolitiniba (u obliku ruksolitinibfosfata)
jakavi 15 mg/1 tableta tableta
novartis ba d.o.o. - ruksolitinib - tableta - 15 mg/1 tableta - 1 tableta sadrži: 15 mg ruksolitiniba (u obliku ruksolitinibfosfata)
jakavi 20 mg/1 tableta tableta
novartis ba d.o.o. - ruksolitinib - tableta - 20 mg/1 tableta - 1 tableta sadrži: 20 mg ruksolitiniba (u obliku ruksolitinibfosfata)
jakavi 10 mg/1 tableta tableta
novartis ba d.o.o. - ruksolitinib - tableta - 10 mg/1 tableta - 1 tableta sadrži: 10 mg ruksolitiniba (u obliku ruksolitinibfosfata)
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
kanazol 100 mg/1 kapsula kapsula, tvrda
pharmavision bh d.o.o. - itrakonazol - kapsula, tvrda - 100 mg/1 kapsula - 1 kapsula sadrži itrakonazol 100 mg